InnoBio Fund and Lundbeckfond Ventures lead $25.5m round for DBV Technologies, which includes Shire.
DBV Technologies, a France-based biotechnology company to combat food allergies, has raised $25.5m in its series C round from a group including UK and Nasdaq-listed drugs group Shire in its first corporate venturing deal.
The round was co-led by new investors InnoBio Fund and Lundbeckfond Ventures. InnoBio is a fund managed by venture capital (VC) firm CDC Entreprises and sponsored by the French state’s sovereign fund FSI and pharmaceutical companies, including Sanofi Aventis, GlaxoSmithKline, Roche, Novartis, Pfizer, Lilly, Ipsen, Takeda…
